Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 5023 word(s) 5023 2021-09-14 06:15:24 |
2 format correct -13 word(s) 5010 2021-09-24 03:13:05 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Fazal, S. BMVs for Drug Delivery Applications. Encyclopedia. Available online: (accessed on 19 June 2024).
Fazal S. BMVs for Drug Delivery Applications. Encyclopedia. Available at: Accessed June 19, 2024.
Fazal, Sajid. "BMVs for Drug Delivery Applications" Encyclopedia, (accessed June 19, 2024).
Fazal, S. (2021, September 24). BMVs for Drug Delivery Applications. In Encyclopedia.
Fazal, Sajid. "BMVs for Drug Delivery Applications." Encyclopedia. Web. 24 September, 2021.
BMVs for Drug Delivery Applications

Numerous factors need to be considered to develop a nanodrug delivery system that is biocompatible, non-toxic, easy to synthesize, cost-effective, and feasible for scale up over and above their therapeutic efficacy. With regards to this, worldwide, exosomes, which are nano-sized vesicles obtained from mammalian cells, are being explored as a biomimetic drug delivery system that has superior biocompatibility and high translational capability. However, the economics of undertaking large-scale mammalian culture to derive exosomal vesicles for translation seems to be challenging and unfeasible. Recently, Bacterial Membrane Vesicles (BMVs) derived from bacteria are being explored as a viable alternative as biomimetic drug delivery systems that can be manufactured relatively easily at much lower costs at a large scale. Until now, BMVs have been investigated extensively as successful immunomodulating agents, but their capability as drug delivery systems remains to be explored in detail. 

biomimetics bacterial membrane vesicles nanoparticles drug delivery antibiotic therapy

1. Introduction

For developing translatable engineered nanomedical systems for therapeutic and diagnostic applications, it is essential to consider the various different engineering and biological roadblocks these would encounter on the path to translation. From the engineering standpoint, large scale uniform production of nanoparticle (NP) systems is difficult to achieve primarily because of the complexity in their design [1][2], which leads to manufacturing difficulties in scale-up, quality control issues, downstream purification complexities, and increased cost of production. While from the biological standpoint, the immunogenicity of the NP system as a whole as well as its individual components, nanotoxicity, and overall therapeutic efficacy can further hinder its translatability [3][4] (Figure 1). In the past decade, there has been a collective effort towards addressing these issues, especially with concerns regarding the immunogenicity and biocompatibility of the designed NPs. Specifically, there has been a rise in research related to the development of NP systems that partly resemble or mimic non-immunogenic biological entities called as biomimetic/bioinspired NPs [5][6][7]. Such biomimetic/bioinspired NPs are considered to not only be non-immunogenic with reduced toxicity, but also possess superior pharmacokinetic properties [8][9][10] (due to lower macrophage clearance), paving the way for extensive research regarding their use for various therapeutic and imaging applications.
Figure 1. (A) Conventional NPs synthesized routinely in laboratories could face many more roadblocks on the path to clinical translation as compared to (B) biomimetic NPs. On the other hand, (C) BMV-based nanomedical systems could benefit over other biomimetic NPs as they have the potential to be easily mass produced.
These biomimetic/bioinspired nanoparticles are considered to possess several advantages as compared to conventional NP systems composed of polymeric and inorganic materials. The most important advantage that they provide is their high biodegradability and non-toxic degradation products that can be easily cleared from the body without eliciting any long-term toxicity and bioaccumulation effects. Additionally, as the building blocks for the synthesis of such NPs are biomolecules, they can be harnessed directly from biological sources, which in some cases (e.g., albumin) can be obtained in large scale at low cost. Biomimetic/bioinspired NPs have been reported to be synthesized through a number of different materials and approaches which include (a) nanoparticles derived directly from biomolecules, (b) biomaterial coated nanoparticles, and (c) cell membrane-coated nanoparticles (Table 1, Figure 2). Nanoparticles that are derived directly from biomolecules are designed using a bottom to top synthesis strategy wherein biologically derived components such as albumin [11], casein [12][13], starch [14][15], gelatin [16][17], etc. are used directly to engineer and assemble the NP system that is loaded with a cargo of interest. Of note, the FDA-approved nanomedicine Abraxane®, which consists of the chemotherapeutic drug paclitaxel bound to albumin [18], is a prime example of this type of NP. Additionally, these biomolecules have also been used for coating NP surfaces in order to combine their biocompatibility with the desired functional ability of engineered NPs [19][20]. This strategy is particularly important since the pharmacokinetic property of a drug delivery system is primarily dependent on its surface physicochemical properties. By appropriately coating a functional polymeric/inorganic NP system with suitable biomolecules (Table 1), its interaction with different blood components in the body (including proteins and macrophages) is favorably altered so as to impart improved circulation time, higher bioavailability, and reduced clearance. Another widely used approach that has gained widespread attention involves the surface modification of synthetic NPs with cell membrane components [21] obtained from cells such as erythrocytes [22][23][24], platelets [25][26][27], macrophages [28][29][30], etc. This leads to the creation of a phospholipid bilayer surface on the NPs, thus affording them advantageous properties similar to that of liposomal structures. This strategy can be considered to be superior as compared to biomolecule coating, since the transfer of cell membrane components and the corresponding functional proteins (including cell membrane receptors, signaling proteins, etc.) provide added functionality to the NP system as a whole such as cancer cell targeting, immune evasion, biobarrier penetration, etc.
Figure 2. Depiction of different types of biomimetic/bioinspired NPs that have been reported in literature. (A) NPs synthesized directly from a biomolecule. (B) Surface modification of synthesized NPs with biomolecular structures. (C) Coating of synthesized NPs with cell membrane surfaces derived from mammalian cells. (D) Direct utilization of nano-sized extracellular vesicles/bacterial membrane vesicles isolated from mammalian or bacteria cells respectively.
Table 1. Different types of biomimetic/bioinspired NPs reported in literature.
Type Biological Source Cargo Loaded/NP Application Reference
Biomolecule assembly Human Serum albumin Indocyanine green Active targeting and photothermal therapy of NIH-3T6.7 tumor (in vivo) [31]
Casein 10-hydroxycamptothecin Drug delivery to C6 glioma tumor (in vivo) [32]
Human transferrin Near-infrared dye IR-780 Photodynamic and photothermal therapy of CT26 colon carcinoma (in vivo) [33]
Human H-ferritin Doxorubicin Drug delivery to U87MG human glioma [34]
Surface modification Bovine serum albumin Silver NPs Photothermal ablation of B16F10 murine melanoma (in vitro) [35]
Casein Iron-Oxide NPs Active EGFR targeting (in vitro) and MRI contrast (in vivo) [36]
High density lipoprotein gold NPs Nucleic acid delivery to PC3 prostate cancer cells (in vitro) [37]
Mammalian cell membrane-coated NPs Erythrocytes poly(lactic-coglycolic) acid NPs Toxin removal- demonstrated in mouse sepsis model [22]
Neural stem cells poly(lactic-coglycolic) acid NPs Glyburide delivery for stroke treatment (in vivo) [38]
Platelets poly(lactic-coglycolic) acid NPs Rapamycin delivery for atherosclerosis treatment (in vivo) [26]
Mouse leukemia cell C1498 poly(lactic-coglycolic) acid NPs Active targeting and delivery of dexamethasone del for treatment of lung infection (in vivo) [39]
In contrast to the above methods of synthesis of biomimetic/bioinspired NPs, there is another approach that has recently gained widespread attention in the area of nanomedicine research. This involves the direct use of naturally synthesized extracellular vesicles [40] that are ubiquitously found to be produced by all cells (Figure 2D). Among the different types of extracellular vesicles such as microvesicles, exosomes and apoptotic bodies, the nano-sized extracellular vesicles called ‘exosomes’ obtained either from mammalian cells [41][42][43] or ‘Bacterial Membrane Vesicles (BMV)’ obtained from bacteria [44][45], have been demonstrated as excellent drug delivery agents particularly owing to their nanoscale size. Unlike other conventional nanoparticles that could have a solid core structure, the nanovesicle structures have a hollow hydrophilic interior (similar to liposomes) and can be used to transport drugs and other cargo. These naturally derived vesicles will exhibit a surface chemical composition identical to the parent cell from which they are obtained, and therefore would demonstrate high biocompatibility and low immunogenicity. Such favorable characteristics make them ideally suited for easy translation from a biological standpoint. Moreover, as they are biologically synthesized by cells directly, no chemical synthesis step would be required for their production and they can be produced by optimizing the cell culture and growth condition.
Even though such biomimetic nanovesicles could make it easier to scale the biological roadblock of clinical translation, it is important to overcome the large-scale design and engineering roadblocks with regards to their synthesis. Taking this into consideration, exosomes derived from mammalian cells would be particularly difficult to translate due to the challenge involved in undertaking large-scale mammalian cell culture to obtain exosomes in large quantities, in addition to the high cost for maintaining mammalian cell culture conditions at an industrial scale [46]. In this regard, exosomes obtained from bacterial sources, i.e., BMVs, could have high translation potential. The mass production of bacteria in bacterial growth tanks would be relatively easier to accomplish and the subsequent associated costs would also be relatively low [47], as compared to mammalian cell cultures. Additionally, a unique advantage associated with utilizing bacteria for BMV synthesis is their ease of genetic engineering which can help specifically design and produce BMVs with functional moieties [48]. In this review, the biomedical applications of BMVs are discussed with regards to their use as drug delivery vehicles for cancer therapy and antibacterial therapy. Particularly, attention will be focused on the bacterial sources for BMV production, their separation and purification, characterization techniques, drug loading strategies, and their in vivo biomedical applications reported thus far.

2. Types of BMVs and Factors Affecting Their Synthesis

Broadly, two different types of BMVs can be considered to exist based on the Gram staining of the bacterial source from which they are produced. BMVs that are secreted from Gram-negative bacteria are generally termed Outer Membrane Vesicles (OMVs), while those that are secreted from Gram-positive bacteria are simply called membrane vesicles (MVs) or Cytoplasmic Membrane Vesicles (CMVs). The reason the BMVs secreted from Gram-negative bacteria are called OMVs is because they originate from the outer membrane of the complex cell envelope [49] that encompasses the Gram-negative bacteria (Figure 3). On the other hand, MVs synthesized from Gram-positive bacteria originate directly from the cytoplasmic membrane of the simple Gram-positive bacterial cell wall [50]. Apart from these typical BMVs, several other structures such as Outer–Inner Membrane vesicles [51], Explosive Outer Membrane Vesicles [52], and Tube-shaped Membranous structures [53] have also been identified to be secreted by bacterial cells.
Figure 3. Origin of BMVs differ in gram negative and gram positive bacteria due to the inherent differences in the cell membrane structure.
Even though the route of synthesis of BMVs is not clearly understood, several hypotheses for the same can be made by evaluating their composition and relative concentrations of protein, lipids, and nucleic acid contents [54]. As OMVs contain lipids and proteins that are typically present in the outer membrane and periplasmic space of their parent source bacteria, they are considered to originate from the gram negative bacterial outer membrane through cell membrane blebbing mechanisms [55]. On the other hand, Outer–Inner Membrane vesicles, which consist of two membrane layers (from both the outer membrane and inner membrane), additionally contain cytoplasmic protein and DNA and are considered to originate from the inner membrane of Gram-negative bacteria, by pinching off cytoplasmic cell components [51][56][57]. Outer–Inner Membrane vesicles are sometimes also found to contain chromosomal DNA, in which case they are considered to originate due to explosive cell lysis that result in cell death [52][58]. The synthesis of OMVs in Gram-negative bacteria are thought to occur due to defects in the peptidoglycan layer of the bacterial cell wall which can lead to the dissociation of the outer membrane. These defects can arise due to a number of factors such as disrupted crosslinking between the peptidoglycan and the outer membrane [59][60], accumulation of misfolded proteins in the periplasmic space [61][62], and through ‘bilayer coupling’ effects that are brought about by molecules that induce membrane curvatures [63][64]. Another possible mechanism for vesicle blebbing involves the action of the endolysin/autolysin enzyme, that can degrade the peptidoglycan layer. In Gram-negative bacteria, the action of endolysin leads to membrane instability that causes explosive cell lysis and eventual vesiculation [52][65]. For Gram-positive bacteria, the cytoplasmic membrane vesicles are considered to arise either from dying cells [65] or from other conservative blebbing mechanisms [56]. Here, the action of endolysin/autolysin is also considered to play a key role in the formation of CMVs. However, as Gram-positive bacteria have a thicker peptidoglycan layer, membrane instability effects are relatively less pronounced which led to the protrusion of the cytoplasmic membrane through pores in the peptidoglycan layer eventually leading to the release of CMVs.
A number of different genetic and environmental factors can affect vesicle formation in bacteria. Genetic factors can predispose a bacterium to produce more vesicles due to the accumulation of misfolded proteins in the peptidoglycan layer or due to lipid and protein composition in the outer membrane that can affect membrane curvature or cell envelope cross-linking. An example of a hypervesiculating bacteria is the Escherichia coli JC8031 produced by the genetic knockout of tolRA gene, that leads to membrane instability in the E. coli cell envelope [66]. Due to this hypervesiculating nature, E. coli JC8031 has been explored for various biomedical applications including the development of vaccines [67][68] and for drug delivery (discussed below). Environmental factors including bacterial growth conditions, medium composition, and other stress factors (including thermal stress [69][70] and antibiotic stress [71]) can also increase the release of BMVs.
BMVs play important roles including intracellular communication such as horizontal gene transfer between different bacterial species [72][73], immunomodulation in a potential host [74], aiding the formation of bacterial biofilms [75], and many others. In the human body, BMVs not only play important role in bacterial infection, but also play a protective role in preventing inflammation such as from commensal bacteria that reside in the gut [76]. Information regarding their structural composition, functions and mechanism of action are not yet fully unraveled, however readers are referred to exhaustive resources [77][78] that provide up-to date knowledge regarding these.

3. Drug Delivery Applications of BMVs

The therapeutic application of BMVs has largely been explored pre-clinically for its use as an immune-modulating agent [79][80][81]. This is primarily because of the presence of antigenic protein molecules in BMVs which when used, may trigger a favorable immune response in the body. Until now this phenomenon has been successfully translated to clinics for the development of a vaccine against Neisseria meningitidis serogroup B (Bexsero® developed by Novartis) [82]. In some cases, BMVs have been demonstrated to amplify the immunogenicity of a low immunogenic protein antigen by acting as a vaccine delivery system [83][84]. Additionally, the ease of genetic modification of the bacterial source has also contributed to it being utilized as an efficient and promising immunomodulator.
The use of BMVs for drug/cargo delivery applications has only been explored recently with only a handful of published literature reports. Most of the applications for BMVs has primarily been focused either on cancer therapy or antibacterial therapy (Figure 4).
Figure 4. Different applications of BMVs reported in literature for (A) cancer therapy and (B) antibacterial therapy.

3.1. Cancer Therapy

In one such report, BMVs isolated from non-pathogenic attenuated K. pneumoniae were utilized for the delivery of doxorubicin [85]. Anti-tumor studies carried out using such BMVs at a dose of 2 mg/Kg of DOX (injected intraperitoneally every day for 11 days) in A549 tumor bearing BALB/c nude mice showed a significant reduction in tumor volume as compared to the use of free drug, empty BMVs, and even doxorubicin-loaded liposomes (Figure 5A). In fact, it was observed that the rate of reduction in tumor volumes was found to be greater for DOX-loaded BMVs as compared to DOX-loaded liposomes, signifying that BMVs showed a better therapeutic response. This added therapeutic response observed in DOX-loaded BMVs could be attributed to the favorable immune response that BMVs can induce in vivo which in conjunction with chemotherapeutic drugs leads to generation of a higher therapeutic efficacy. This was supported by tumor volume reduction studies in the same report that showed that the use of bare BMVs alone in vivo lead to a significant reduction in tumor volume as compared to untreated controls. Further, it was also observed that there occurred a significant accumulation of murine macrophages in tumor tissues that were treated with both doxorubicin loaded BMVs and empty BMVs. Pharmacokinetic analysis showed that the use of drug loaded BMVs lead to a greater drug retention in tumors that lasted for longer periods of time as compared to DOX-loaded liposomes with a concurrently lower retention found in the heart (Figure 5B). As a result, the cardiac toxicity (which is notable in the use of doxorubicin) was found to be significantly reduced when DOX-loaded BMVs were used (as measured through analysis of lactate dehydrogenase, aspartate aminotransferase, and creatine kinase isoenzyme in blood), which were further supported through histopathological analysis of cardiac tissues. Overall, the pharmacokinetic profile of the loaded drug was improved (characterized by an increase in the drug half-life, reduction in clearance rate, and improved bioavailability) when BMVs were utilized as a drug delivery vehicle. Immunotoxicity analysis in C57BL/6 normal mice at the therapeutic dosage (over a period of 11 days) showed that the administration of both DOX-loaded BMVs and bare BMVs lead to a significant increase in serum cytokine levels which returned back to basal levels over a period of time. These results therefore showed that BMVs could be well tolerated in vivo and could be used as an effective drug delivery vehicle.
Figure 5. (A) Tumor volume reduction measurements and (B) in vivo drug distribution of doxorubicin-loaded K. pneumoniae OMVs as compared to controls. Reproduced from [85], Elsevier, 2020.
Similar to the above, a study depicting the use of S. typhimurium BMVs for combined drug delivery and immunotherapy against cancer was reported [86]. In vivo tumor therapy studies carried out using hybrid BMVs (BMV/micelle/drug) in B16F10 melanoma and 4T1 mammary tumor in C57BL/6 mice at a dose of 30 µg of BMVs (once/3 days for a total of 3 injections) lead to a significant reduction in tumor volume and increase in survival as compared to controls. Furthermore, this treatment also limited the spread of cancer metastatic nodules in lung tissues, which otherwise are prevalent in the B16F10 tumor model, which could explain the increase survival of mice observed on treatment. Interestingly, the synthesized BMVs also showed an immunoprotective effect against tumor. Mice that were pretreated with BMVs, when challenged with tumor cells later on, showed a delayed tumor growth response with significantly small tumor volumes (Figure 6). Even though the exact reasons for the same have not been elucidated in this report, these results show overall the promising effect that BMVs have towards developing a strategy for tumor prevention and treatment. Upon BMV administration, the in vivo cytokine analysis of blood and tumor samples showed that even though there occurred an increase in the cytokine levels of TNF-α, IFN-γ, IL-12, IL-4, and IL-17, the levels of these cytokine reduced to basal levels after 24 h. Overall, no blood toxicity and organ toxicity (including liver and renal functions) were found upon BMV administration.
Figure 6. (A) Treatment timeline for evaluating the protective role of hybrid BMVs (drug-loaded micelles surface modified with BMVs)—hybrid BMVs were administered to mice before tumor challenge. (B) Percentage of tumor-free mice after tumor challenge (C) Mean tumor volume measurements of hybrid OMVs against controls (Teg-Tegafur, FT-Tegafur loaded F127 micelle, OR-RGD functionalized BMV, ORFT—Tegafur-loaded F127 micelle surface modified with RGD functionalized BMV). Reproduced with permission from [86], American Chemical Society, 2020.
Even though the above studies showed the ability of BMVs as a promising drug delivery agent, an interesting study has demonstrated its ability to be used as in its native form as a potential anti-tumor immunotherapeutic agent [87]. To demonstrate its applicability, unmodified BMVs isolated from both Gram-negative and -positive bacterial species were assessed for their ability to actuate an anti-tumor immune response in different tumor models in mice. Specifically, BMVs isolated from Gram-negative E. coli and S. Enterica and Gram-positive S. aureus and L. acidophilus were injected intravenously in BALB/c mice bearing CT26 colon adenocarcinoma at a 5 µg BMV dose (4 times at 3 days interval), significant tumor volume reductions were observed as compared to PBS injected controls (Figure 7A,B). Additionally, to demonstrate its diverse potential, BMVs from E. coli were assessed for their therapeutic response in CT26 colon adenocarcinoma and 4T1 mouse mammary tumor of BALB/c mice, and MC38 mouse colon adenocarcinoma and B16BL6 mouse melanoma cancer of C57BL/6 mice. At a 5 µg E. coli BMV dose injected intravenously (4 times at 3 days interval), significant tumor volume reductions were observed for all the treated tumor types. However, the reduction in tumor volumes in 4T1 and B16BL6 tumors were found to be less effective as compared to those observed in CT26 and MC38 tumors, which shows the important role tumor biology and characteristics have on the net therapeutic outcome. Interestingly, for the treatment of CT26 tumors, a long-term memory effect was observed for treatment using E. coli BMVs wherein secondary and tertiary challenges of CT-26 tumor cells were rejected in mice that recovered from the primary tumor challenge post BMV administration. These results show how BMVs have the ability to favorably modulate the immune system and possibly provide a protective environment to prevent tumor relapse as observed for other immunotherapeutic modalities [88]. Similar to other reports on the use of BMVs in vivo, an increase in the levels of cytokines and chemokines such as IL-12p40, IFN-γ, CXCL10, TNF-α, IL-6, and IL-12p70 were also observed in this study. However, it was observed that the cytokines CXCL10 and IFN-γ specifically showed elevated levels in the tumor tissues over 24 and 48 h which could imply that these cytokines play an important role in eliciting an anti-tumor immune response (Figure 7C,D).
Figure 7. Tumor volume measurement study for CT26 tumors injected with (A) Gram-positive S. Aureus, lipoteichoic acid S. Aureus mutant, and L. Acidophilus. (B) Gram-negative E. coli and S. enterica. Measurement of (C) IFN-γ and (D) CXCL10 cytokine levels in tumor cell lysate at different time points after E. coli BMV administration in CT26 tumors (** p < 0.01, and *** p < 0.001). Reproduced with permission from [87], Springer Nature, 2017.
Apart from utilizing BMVs for drug loading, BMVs have also been utilized for the delivery of therapeutic nucleic acids for the treatment of cancer. By loading siRNA targeting kinetic spindle protein, a protein essential for spindle formation and continuation of cell cycle, into BMVs obtained from ΔmsbB E. coli, in vivo treatment of liver cancer was demonstrated [89]. Significant reduction of HCC-1954 xenografts in nude mice was observed upon intravenous administration of siRNA-loaded BMVs at a 4 µg dose siRNA injected on alternate days over a 22-day treatment period as compared to controls. Serum cytokine analysis showed elevated levels of TNF alpha, IL6, and IFNγ in C57BL/6 mice upon repeated dosing (at 10–20 µg siRNA) over 4 consecutive days. However, this elevation was observed only for a brief period of 3 h post-administration and would return back to basal levels in 24 h. Note that lethal dose toxicity studies showed that the BMVs obtained from ΔmsbB E. coli did not cause any mortality even at a single high dose of 100 µg, while, on the other hand, administration of 50 µg of BMVs obtained from wild type E. coli lead to mortality within 48 h post administration. This shows how the biochemical composition of the surface moieties of BMVs play a crucial role in its toxicity response. Here, the ΔmsbB mutation in E. coli produces underacylated LPS which shows reduced endotoxicity.
While BMVs show great promise as a drug delivery vehicle, one report has gone further to evaluate its potential as a stimuli-responsive multifunctional theranostic agent [90]. To do so, BMVs synthesized from ΔmsbB E. coli were loaded with melanin (which can act both as a photoacoustic and photothermal agent), by introducing the required plasmid to the bacteria. This led to the generation of melanin which is packed within the BMV lumen. Upon laser exposure, a concentration dependent thermal response was observed for melanin loaded BMVs, which when used in vitro produced significant cell death due to the photothermal effect (Figure 8A,B). When such melanin-loaded BMVs were administered in 4T1 mammary tumor-bearing FOX-N-1 nude mice intravenously at a single dose of ~150 µg protein, optoacoustic signals could be observed in tumor, liver, and kidneys, enabling the study of its biodistribution profile. The imaging results demonstrated that these BMVs accumulated in the tumor through EPR effects, underwent continuous circulation in vivo, and cleared slowly from the system over a period of 24 h. Photothermal treatment of the 4T1 tumors 3 h post-injection of a single dose of ~75 µg BMVs lead to a significant thermal response of 56 °C and 47 °C for intratumoral and intravenous administration respectively. This resulted in a significant reduction in tumor volume over an 8 days period after just a single treatment and laser therapy which its high effectiveness in cancer therapy (Figure 8C,D). As previous studies have pointed out, there occurred a significant increase in the cytokine levels of TNF-α, IL-6, and IFN-γ 2 h post administration of BMVs, which however reduced near to the baseline levels after 25 h.
Figure 8. (A) Thermal response of melanin-loaded OMVs at different concentrations as compared to wild type OMVs upon laser exposure. (B) Live–dead (calcein AM/EthD-1) staining of 4T1 cancer cells treated with melanin-loaded OMVs and exposed to laser as compared to controls. Thermal imaging (C) and tumor volume reduction measurements (D) of 4T1 tumors after either intravenous or intratumoral administration of melanin loaded OMVs and laser exposure as compared to controls. Reproduced with permission from [90], Springer Nature, 2019.

3.2. Antibacterial Therapy

The use of BMVs for antibacterial applications has mostly been investigated by utilizing the inherent antigenic molecules present on BMV surface for eliciting a favorable immune response against the invading pathogen. In this regard, BMVs have been utilized either directly in its unmodified form [91] or modified appropriately to present the antigenic proteins with a suitable material to elicit a desired immune response. One way of presenting antigenic proteins to the immune system is through the use of NPs, which can maximize immune cell recognition owing to their large surface area and size scale that facilitates particle uptake [92][93][94]. Numerous literature reports have utilized this methodology to develop nanotechnology-based vaccines and similar approaches have been demonstrated with BMVs for antibacterial therapy.
To demonstrate the potential of NP-based immunomodulation by utilizing BMV antigen proteins, surface-modified Au NPs have been investigated in vivo for antibacterial therapy applications [95]. Upon intravenous administration of BMV protein-coated Au NPs (2.5 µg dose) into immunocompetent CD-1 mice, a number of highly precise immune responses were observed as compared to bare BMVs and PBS injected controls. Specifically, it was observed that BMV-coated Au NPs lead to a heighted activation and maturation of dendritic cells and T cells and an increased B cell response and a consequent increase in antibody titers. Note, in this study, that when smaller sized Au NPs (~30 nm) were used as compared to larger sized Au NPs (~90 nm) a relatively heighted dendritic cell activation and maturation was observed. This was found to be due to the better accumulation of smaller sized Au NPs in the lymph nodes of mice, thereby making them more suitable for immune activation. However, in this study the application of these BMV protein surface-modified Au NPs was not evaluated in an infection model.
In an interesting report, BMVs were utilized to surface modify polymeric NP-based antibiotic delivery systems such that target specificity could be achieved [96]. Preliminary in vitro studies undertaken by this group showed that BMVs isolated either from E. coli or S. aureus showed specific uptake in macrophages that were pre-infected with E. coli or S. aureus, respectively. As a result, antibiotic-loaded PLGA NPs surface modified with S. aureus BMVs were found to show significantly greater accumulation in major organs of an S. aureus infected BALB/c mice model as compared to E. coli BMV-coated PLGA NPs and liposome-coated PLGA NPs. This greater internalization was explained to be caused by the greater ability of infected macrophages to internalize the NPs first, followed by the natural biodistribution of these macrophages to the infected organs. As a result of this greater accumulation observed for the S. aureus BMV-coated antibiotic loaded PLGA NPs, effective reduction of bacterial CFU counts could be observed in kidneys and lungs of the infected mice. However, note here that effective therapeutic efficacy could not be achieved for all major organs, and more studies need to be carried out to exploit this specific property of BMV-coated NPs. It would be interesting to study in this case if the specific uptake of BMV-coated NPs in infected macrophages could be extended to other infected mammalian cells and cancer cells. If such a specificity could be achieved, it could open up the possibility of treating patients with tumors bearing bacterial load. Such infected tumor conditions are nowadays observed in clinical investigations and the presence of these bacteria in tumors are found to play an important role in inhibiting the efficacy of chemotherapeutic drug treatments [97][98].
Beyond the use of BMVs, one unique report demonstrated the direct use of bacterial cells for NP surface modification [99]. Here, bacterial protoplasts were first isolated by treating bacteria with lysozyme to remove the bacterial cell wall, followed by its serial extrusion through 10, 5, and 1 µm sized polycarbonate membrane filters. These protoplast-derived nanovesicles (PDNVs) show inherent advantage over BMVs as they can be directly synthesized in large amounts from the bacterial suspension. Additionally, due to removal of the bacterial cell wall, the resultant PDNVs were depleted of the outer membrane proteins OmpA and lipid A which are components of LPS, thus making them less immunogenic and more favorable for drug delivery and theranostic applications. Here, for investigating its immunotherapeutic potential, PDNVs were loaded separately either with E. coli antigen OmpA and S. aureus antigen Scoagulase by expressing the desired antigen in the parent E. coli bacterium. The resultant PDNVs, when administered in vivo in C57BL/6 mice, showed high specificity in developing an immune-protective response against bacterial challenge. Specifically, it was observed that PDNVs harboring either the OmpA antigen or the Scoagulase antigen showed effective immune response in vivo when challenged with lethal doses of E. coli or S. aureus respectively. This response was found to be highly specific with respect to the antigen that the PDNVs harbored such that mice that were administered with PDNVs harbouring E. coli antigen OmpA succumbed when challenged with S. aureus infection, and vice versa. The protective immunity offered by such PDNVs could be observed in mice up to 6 weeks post-administration. Interestingly, these PDNVs were found to show low in vitro and in vivo toxicity as compared to E. coli-derived BMVs. Specifically, it was observed that even upon administration of upto 1 mg of PDNVs in C57BL/6 mice all animals survived, while a dosage of only 25 µg of BMVs lead to the death of 80% of the animals. Overall, PDNVs show great promise towards the development of biomimetic drug delivery vehicles and show several advantages as compared to BMVs.


  1. Hua, S.; de Matos, M.B.C.; Metselaar, J.M.; Storm, G. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. Front. Pharmacol. 2018, 9, 790.
  2. Metselaar, J.M.; Lammers, T. Challenges in nanomedicine clinical translation. Drug Deliv. Transl. Res. 2020, 10, 721–725.
  3. Dobrovolskaia, M.A.; Shurin, M.; Shvedova, A.A. Current understanding of interactions between nanoparticles and the immune system. Toxicol. Appl. Pharmacol. 2016, 299, 78–89.
  4. Hannon, G.; Lysaght, J.; Liptrott, N.J.; Prina-Mello, A. Immunotoxicity Considerations for Next Generation Cancer Nanomedicines. Adv. Sci. 2019, 6, 1900133.
  5. Parodi, A.; Molinaro, R.; Sushnitha, M.; Evangelopoulos, M.; Martinez, J.O.; Arrighetti, N.; Corbo, C.; Tasciotti, E. Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery. Biomaterials 2017, 147, 155–168.
  6. Sushnitha, M.; Evangelopoulos, M.; Tasciotti, E.; Taraballi, F. Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications. Front. Bioeng. Biotechnol. 2020, 8, 627.
  7. Jin, J.; Bhujwalla, Z.M. Biomimetic Nanoparticles Camouflaged in Cancer Cell Membranes and Their Applications in Cancer Theranostics. Front. Oncol. 2019, 9, 1560.
  8. Parodi, A.; Quattrocchi, N.; van de Ven, A.L.; Chiappini, C.; Evangelopoulos, M.; Martinez, J.O.; Brown, B.S.; Khaled, S.Z.; Yazdi, I.K.; Enzo, M.V.; et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 2013, 8, 61–68.
  9. Pasto, A.; Giordano, F.; Evangelopoulos, M.; Amadori, A.; Tasciotti, E. Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy. Clin. Transl. Med. 2019, 8, 8.
  10. Hu, C.-M.J.; Fang, R.H.; Wang, K.-C.; Luk, B.T.; Thamphiwatana, S.; Dehaini, D.; Nguyen, P.; Angsantikul, P.; Wen, C.H.; Kroll, A.V.; et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015, 526, 118–121.
  11. Elzoghby, A.O.; Samy, W.M.; Elgindy, N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release 2012, 157, 168–182.
  12. Penalva, R.; Esparza, I.; Agüeros, M.; Gonzalez-Navarro, C.J.; Gonzalez-Ferrero, C.; Irache, J.M. Casein nanoparticles as carriers for the oral delivery of folic acid. Food Hydrocoll. 2015, 44, 399–406.
  13. Malekhosseini, P.; Alami, M.; Khomeiri, M.; Esteghlal, S.; Nekoei, A.-R.; Hosseini, S.M.H. Development of casein-based nanoencapsulation systems for delivery of epigallocatechin gallate and folic acid. Food Sci. Nutr. 2019, 7, 519–527.
  14. Ahmad, M.; Gani, A.; Hassan, I.; Huang, Q.; Shabbir, H. Production and characterization of starch nanoparticles by mild alkali hydrolysis and ultra-sonication process. Sci. Rep. 2020, 10, 3533.
  15. Le Corre, D.; Bras, J.; Dufresne, A. Starch nanoparticles: A review. Biomacromolecules 2010, 11, 1139–1153.
  16. Ethirajan, A.; Schoeller, K.; Musyanovych, A.; Ziener, U.; Landfester, K. Synthesis and optimization of gelatin nanoparticles using the miniemulsion process. Biomacromolecules 2008, 9, 2383–2389.
  17. Kuo, W.T.; Huang, J.Y.; Chen, M.H.; Chen, C.Y.; Shyong, Y.J.; Yen, K.C.; Sun, Y.J.; Ke, C.J.; Cheng, Y.H.; Lin, F.H. Development of gelatin nanoparticles conjugated with phytohemagglutinin erythroagglutinating loaded with gemcitabine for inducing apoptosis in non-small cell lung cancer cells. J. Mater. Chem. B 2016, 4, 2444–2454.
  18. Desai, N. Nanoparticle Albumin-Bound Paclitaxel (Abraxane®). In Albumin in Medicine: Pathological and Clinical Applications; Otagiri, M., Chuang, V.T.G., Eds.; Springer: Singapore, 2016; pp. 101–119.
  19. Mariam, J.; Sivakami, S.; Dongre, P.M. Albumin corona on nanoparticles—A strategic approach in drug delivery. Drug Deliv. 2016, 23, 2668–2676.
  20. Naha, P.C.; Liu, Y.; Hwang, G.; Huang, Y.; Gubara, S.; Jonnakuti, V.; Simon-Soro, A.; Kim, D.; Gao, L.; Koo, H.; et al. Dextran-Coated Iron Oxide Nanoparticles as Biomimetic Catalysts for Localized and pH-Activated Biofilm Disruption. ACS Nano 2019, 13, 4960–4971.
  21. Raza, F.; Zafar, H.; Zhang, S.; Kamal, Z.; Su, J.; Yuan, W.E.; Mingfeng, Q. Recent Advances in Cell Membrane-Derived Biomimetic Nanotechnology for Cancer Immunotherapy. Adv. Healthc. Mater. 2021, 10, e2002081.
  22. Ben-Akiva, E.; Meyer, R.A.; Yu, H.; Smith, J.T.; Pardoll, D.M.; Green, J.J. Biomimetic anisotropic polymeric nanoparticles coated with red blood cell membranes for enhanced circulation and toxin removal. Sci. Adv. 2020, 6, eaay9035.
  23. Hu, C.M.; Zhang, L.; Aryal, S.; Cheung, C.; Fang, R.H.; Zhang, L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. USA 2011, 108, 10980–10985.
  24. Xia, Q.; Zhang, Y.; Li, Z.; Hou, X.; Feng, N. Red blood cell membrane-camouflaged nanoparticles: A novel drug delivery system for antitumor application. Acta Pharm. Sin. B 2019, 9, 675–689.
  25. Wei, X.; Ying, M.; Dehaini, D.; Su, Y.; Kroll, A.V.; Zhou, J.; Gao, W.; Fang, R.H.; Chien, S.; Zhang, L. Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis. ACS Nano 2018, 12, 109–116.
  26. Song, Y.; Huang, Z.; Liu, X.; Pang, Z.; Chen, J.; Yang, H.; Zhang, N.; Cao, Z.; Liu, M.; Cao, J.; et al. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE(-/-)) mice. Nanomedicine 2019, 15, 13–24.
  27. Wang, S.; Duan, Y.; Zhang, Q.; Komarla, A.; Gong, H.; Gao, W.; Zhang, L. Drug Targeting via Platelet Membrane–Coated Nanoparticles. Small Struct. 2020, 1, 2000018.
  28. Gao, C.; Huang, Q.; Liu, C.; Kwong, C.H.T.; Yue, L.; Wan, J.-B.; Lee, S.M.Y.; Wang, R. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat. Commun. 2020, 11, 2622.
  29. Zhang, Y.; Cai, K.; Li, C.; Guo, Q.; Chen, Q.; He, X.; Liu, L.; Zhang, Y.; Lu, Y.; Chen, X.; et al. Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy. Nano Lett. 2018, 18, 1908–1915.
  30. Chen, L.J.; Zhao, X.; Liu, Y.Y.; Yan, X.P. Macrophage membrane coated persistent luminescence [email protected] mesoporous carbon core-shell nanocomposites for autofluorescence-free imaging-guided chemotherapy. J. Mater. Chem. B 2020, 8, 8071–8083.
  31. Lee, C.; Kang, S. Development of HER2-Targeting-Ligand-Modified Albumin Nanoparticles Based on the SpyTag/SpyCatcher System for Photothermal Therapy. Biomacromolecules 2021, 22, 2649–2658.
  32. Gao, C.; Liang, J.; Zhu, Y.; Ling, C.; Cheng, Z.; Li, R.; Qin, J.; Lu, W.; Wang, J. Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy. Acta Pharm. Sin. B 2019, 9, 843–857.
  33. Wang, K.; Zhang, Y.; Wang, J.; Yuan, A.; Sun, M.; Wu, J.; Hu, Y. Self-assembled IR780-loaded transferrin nanoparticles as an imaging, targeting and PDT/PTT agent for cancer therapy. Sci. Rep. 2016, 6, 27421.
  34. Fan, K.; Jia, X.; Zhou, M.; Wang, K.; Conde, J.; He, J.; Tian, J.; Yan, X. Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma. ACS Nano 2018, 12, 4105–4115.
  35. Kim, D.; Amatya, R.; Hwang, S.; Lee, S.; Min, K.A.; Shin, M.C. BSA-Silver Nanoparticles: A Potential Multimodal Therapeutics for Conventional and Photothermal Treatment of Skin Cancer. Pharmaceutics 2021, 13, 575.
  36. Huang, J.; Wang, L.; Lin, R.; Wang, A.Y.; Yang, L.; Kuang, M.; Qian, W.; Mao, H. Casein-coated iron oxide nanoparticles for high MRI contrast enhancement and efficient cell targeting. ACS Appl. Mater. Interfaces 2013, 5, 4632–4639.
  37. McMahon, K.M.; Mutharasan, R.K.; Tripathy, S.; Veliceasa, D.; Bobeica, M.; Shumaker, D.K.; Luthi, A.J.; Helfand, B.T.; Ardehali, H.; Mirkin, C.A.; et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 2011, 11, 1208–1214.
  38. Ma, J.; Zhang, S.; Liu, J.; Liu, F.; Du, F.; Li, M.; Chen, A.T.; Bao, Y.; Suh, H.W.; Avery, J.; et al. Targeted Drug Delivery to Stroke via Chemotactic Recruitment of Nanoparticles Coated with Membrane of Engineered Neural Stem Cells. Small 2019, 15, e1902011.
  39. Park, J.H.; Jiang, Y.; Zhou, J.; Gong, H.; Mohapatra, A.; Heo, J.; Gao, W.; Fang, R.H.; Zhang, L. Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. Sci. Adv. 2021, 7, abf7820.
  40. Doyle, L.M.; Wang, M.Z. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells 2019, 8, 727.
  41. Kalluri, R.; LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science 2020, 367, aau6977.
  42. Wiklander, O.P.B.; Brennan, M.A.; Lotvall, J.; Breakefield, X.O.; El Andaloussi, S. Advances in therapeutic applications of extracellular vesicles. Sci. Transl. Med. 2019, 11, aav8521.
  43. Dai, J.; Su, Y.; Zhong, S.; Cong, L.; Liu, B.; Yang, J.; Tao, Y.; He, Z.; Chen, C.; Jiang, Y. Exosomes: Key players in cancer and potential therapeutic strategy. Signal Transduct. Target Ther. 2020, 5, 145.
  44. Li, M.; Zhou, H.; Yang, C.; Wu, Y.; Zhou, X.; Liu, H.; Wang, Y. Bacterial outer membrane vesicles as a platform for biomedical applications: An update. J. Control. Release 2020, 323, 253–268.
  45. Wang, S.; Gao, J.; Wang, Z. Outer membrane vesicles for vaccination and targeted drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2019, 11, e1523.
  46. van der Meel, R.; Fens, M.H.; Vader, P.; van Solinge, W.W.; Eniola-Adefeso, O.; Schiffelers, R.M. Extracellular vesicles as drug delivery systems: Lessons from the liposome field. J. Control. Release 2014, 195, 72–85.
  47. Seker, E. Friendly Bacteria. Sci. Transl. Med. 2014, 6, 220ec215.
  48. Li, R.; Liu, Q. Engineered Bacterial Outer Membrane Vesicles as Multifunctional Delivery Platforms. Front. Mater. 2020, 7, 202.
  49. Schwechheimer, C.; Kuehn, M.J. Outer-membrane vesicles from Gram-negative bacteria: Biogenesis and functions. Nat. Rev. Microbiol. 2015, 13, 605–619.
  50. Brown, L.; Wolf, J.M.; Prados-Rosales, R.; Casadevall, A. Through the wall: Extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat. Rev. Microbiol. 2015, 13, 620–630.
  51. Perez-Cruz, C.; Carrion, O.; Delgado, L.; Martinez, G.; Lopez-Iglesias, C.; Mercade, E. New type of outer membrane vesicle produced by the Gram-negative bacterium Shewanella vesiculosa M7T: Implications for DNA content. Appl. Environ. Microbiol. 2013, 79, 1874–1881.
  52. Turnbull, L.; Toyofuku, M.; Hynen, A.L.; Kurosawa, M.; Pessi, G.; Petty, N.K.; Osvath, S.R.; Carcamo-Oyarce, G.; Gloag, E.S.; Shimoni, R.; et al. Explosive cell lysis as a mechanism for the biogenesis of bacterial membrane vesicles and biofilms. Nat. Commun. 2016, 7, 11220.
  53. Remis, J.P.; Wei, D.; Gorur, A.; Zemla, M.; Haraga, J.; Allen, S.; Witkowska, H.E.; Costerton, J.W.; Berleman, J.E.; Auer, M. Bacterial social networks: Structure and composition of Myxococcus xanthus outer membrane vesicle chains. Environ. Microbiol. 2014, 16, 598–610.
  54. Nagakubo, T.; Nomura, N.; Toyofuku, M. Cracking Open Bacterial Membrane Vesicles. Front. Microbiol. 2019, 10, 3026.
  55. Roier, S.; Zingl, F.G.; Cakar, F.; Schild, S. Bacterial outer membrane vesicle biogenesis: A new mechanism and its implications. Microb. Cell 2016, 3, 257–259.
  56. Toyofuku, M.; Nomura, N.; Eberl, L. Types and origins of bacterial membrane vesicles. Nat. Rev. Microbiol. 2019, 17, 13–24.
  57. Dorward, D.W.; Garon, C.F. DNA Is Packaged within Membrane-Derived Vesicles of Gram-Negative but Not Gram-Positive Bacteria. Appl. Environ. Microbiol. 1990, 56, 1960–1962.
  58. Zhou, L.; Srisatjaluk, R.; Justus, D.E.; Doyle, R.J. On the origin of membrane vesicles in gram-negative bacteria. FEMS Microbiol. Lett. 1998, 163, 223–228.
  59. Sonntag, I.; Schwarz, H.; Hirota, Y.; Henning, U. Cell envelope and shape of Escherichia coli: Multiple mutants missing the outer membrane lipoprotein and other major outer membrane proteins. J. Bacteriol. 1978, 136, 280–285.
  60. Schwechheimer, C.; Kulp, A.; Kuehn, M.J. Modulation of bacterial outer membrane vesicle production by envelope structure and content. BMC Microbiol. 2014, 14, 324.
  61. Schwechheimer, C.; Kuehn, M.J. Synthetic effect between envelope stress and lack of outer membrane vesicle production in Escherichia coli. J. Bacteriol. 2013, 195, 4161–4173.
  62. McBroom, A.J.; Kuehn, M.J. Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response. Mol. Microbiol. 2007, 63, 545–558.
  63. Florez, C.; Raab, J.E.; Cooke, A.C.; Schertzer, J.W. Membrane Distribution of the Pseudomonas Quinolone Signal Modulates Outer Membrane Vesicle Production in Pseudomonas aeruginosa. mBio 2017, 8, e1034-17.
  64. Schertzer, J.W.; Whiteley, M. A bilayer-couple model of bacterial outer membrane vesicle biogenesis. mBio 2012, 3, e297-11.
  65. Toyofuku, M.; Carcamo-Oyarce, G.; Yamamoto, T.; Eisenstein, F.; Hsiao, C.C.; Kurosawa, M.; Gademann, K.; Pilhofer, M.; Nomura, N.; Eberl, L. Prophage-triggered membrane vesicle formation through peptidoglycan damage in Bacillus subtilis. Nat. Commun. 2017, 8, 481.
  66. Bernadac, A.; Gavioli, M.; Lazzaroni, J.C.; Raina, S.; Lloubes, R. Escherichia coli tol-pal mutants form outer membrane vesicles. J. Bacteriol. 1998, 180, 4872–4878.
  67. Valentine, J.L.; Chen, L.; Perregaux, E.C.; Weyant, K.B.; Rosenthal, J.A.; Heiss, C.; Azadi, P.; Fisher, A.C.; Putnam, D.; Moe, G.R.; et al. Immunization with Outer Membrane Vesicles Displaying Designer Glycotopes Yields Class-Switched, Glycan-Specific Antibodies. Cell Chem. Biol. 2016, 23, 655–665.
  68. Stevenson, T.C.; Cywes-Bentley, C.; Moeller, T.D.; Weyant, K.B.; Putnam, D.; Chang, Y.F.; Jones, B.D.; Pier, G.B.; DeLisa, M.P. Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies. Proc. Natl. Acad. Sci. USA 2018, 115, E3106–E3115.
  69. de Jonge, E.F.; Balhuizen, M.D.; van Boxtel, R.; Wu, J.; Haagsman, H.P.; Tommassen, J. Heat shock enhances outer-membrane vesicle release in Bordetella spp. Curr. Res. Microb. Sci. 2021, 2, 100009.
  70. McMahon, K.J.; Castelli, M.E.; Vescovi, E.G.; Feldman, M.F. Biogenesis of Outer Membrane Vesicles in Serratia marcescens Is Thermoregulated and Can Be Induced by Activation of the Rcs Phosphorelay System. J. Bacteriol. 2012, 194, 3241–3249.
  71. Huang, W.; Zhang, Q.; Li, W.; Yuan, M.; Zhou, J.; Hua, L.; Chen, Y.; Ye, C.; Ma, Y. Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism. J. Control. Release 2020, 317, 1–22.
  72. Renelli, M.; Matias, V.; Lo, R.Y.; Beveridge, T.J. DNA-containing membrane vesicles of Pseudomonas aeruginosa PAO1 and their genetic transformation potential. Microbiology 2004, 150, 2161–2169.
  73. Domingues, S.; Nielsen, K.M. Membrane vesicles and horizontal gene transfer in prokaryotes. Curr. Opin. Microbiol. 2017, 38, 16–21.
  74. Kuehn, M.J.; Kesty, N.C. Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev. 2005, 19, 2645–2655.
  75. Schooling, S.R.; Beveridge, T.J. Membrane vesicles: An overlooked component of the matrices of biofilms. J. Bacteriol. 2006, 188, 5945–5957.
  76. Shen, Y.; Giardino Torchia, M.L.; Lawson, G.W.; Karp, C.L.; Ashwell, J.D.; Mazmanian, S.K. Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe 2012, 12, 509–520.
  77. Zingl, F.G.; Leitner, D.R.; Schild, S. Biogenesis of Gram-Negative OMVs. In Bacterial Membrane Vesicles: Biogenesis, Functions and Applications; Kaparakis-Liaskos, M., Kufer, T.A., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp. 23–46.
  78. Palacios, A.; Coelho, C.; Maryam, M.; Luque-García, J.L.; Casadevall, A.; Prados-Rosales, R. Biogenesis and Function of Extracellular Vesicles in Gram-Positive Bacteria, Mycobacteria, and Fungi. In Bacterial Membrane Vesicles: Biogenesis, Functions and Applications; Kaparakis-Liaskos, M., Kufer, T.A., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp. 47–74.
  79. Kaparakis-Liaskos, M.; Ferrero, R.L. Immune modulation by bacterial outer membrane vesicles. Nat. Rev. Immunol. 2015, 15, 375–387.
  80. Jiang, L.; Schinkel, M.; van Essen, M.; Schiffelers, R.M. Bacterial membrane vesicles as promising vaccine candidates. Eur. J. Pharm. Biopharm. 2019, 145, 1–6.
  81. Hu, R.; Li, J.; Zhao, Y.; Lin, H.; Liang, L.; Wang, M.; Liu, H.; Min, Y.; Gao, Y.; Yang, M. Exploiting bacterial outer membrane vesicles as a cross-protective vaccine candidate against avian pathogenic Escherichia coli (APEC). Microb. Cell Fact 2020, 19, 119.
  82. Granoff, D.M. Review of meningococcal group B vaccines. Clin. Infect. Dis. 2010, 50 (Suppl. 2), S54–S65.
  83. Chen, D.J.; Osterrieder, N.; Metzger, S.M.; Buckles, E.; Doody, A.M.; DeLisa, M.P.; Putnam, D. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl. Acad. Sci. USA 2010, 107, 3099–3104.
  84. Chen, L.; Valentine, J.L.; Huang, C.J.; Endicott, C.E.; Moeller, T.D.; Rasmussen, J.A.; Fletcher, J.R.; Boll, J.M.; Rosenthal, J.A.; Dobruchowska, J.; et al. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proc. Natl. Acad. Sci. USA 2016, 113, E3609–E3618.
  85. Kuerban, K.; Gao, X.; Zhang, H.; Liu, J.; Dong, M.; Wu, L.; Ye, R.; Feng, M.; Ye, L. Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung cancer. Acta Pharm. Sin. B 2020, 10, 1534–1548.
  86. Chen, Q.; Bai, H.; Wu, W.; Huang, G.; Li, Y.; Wu, M.; Tang, G.; Ping, Y. Bioengineering Bacterial Vesicle-Coated Polymeric Nanomedicine for Enhanced Cancer Immunotherapy and Metastasis Prevention. Nano Lett. 2020, 20, 11–21.
  87. Kim, O.Y.; Park, H.T.; Dinh, N.T.H.; Choi, S.J.; Lee, J.; Kim, J.H.; Lee, S.-W.; Gho, Y.S. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat. Commun. 2017, 8, 626.
  88. Emens, L.A.; Ascierto, P.A.; Darcy, P.K.; Demaria, S.; Eggermont, A.M.M.; Redmond, W.L.; Seliger, B.; Marincola, F.M. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur. J. Cancer 2017, 81, 116–129.
  89. Gujrati, V.; Kim, S.; Kim, S.H.; Min, J.J.; Choy, H.E.; Kim, S.C.; Jon, S. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano 2014, 8, 1525–1537.
  90. Gujrati, V.; Prakash, J.; Malekzadeh-Najafabadi, J.; Stiel, A.; Klemm, U.; Mettenleiter, G.; Aichler, M.; Walch, A.; Ntziachristos, V. Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging. Nat. Commun. 2019, 10, 1114.
  91. Schulz, E.; Goes, A.; Garcia, R.; Panter, F.; Koch, M.; Muller, R.; Fuhrmann, K.; Fuhrmann, G. Biocompatible bacteria-derived vesicles show inherent antimicrobial activity. J. Control. Release 2018, 290, 46–55.
  92. Kishimoto, T.K.; Maldonado, R.A. Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance. Front. Immunol. 2018, 9, 230.
  93. Ben-Akiva, E.; Est Witte, S.; Meyer, R.A.; Rhodes, K.R.; Green, J.J. Polymeric micro- and nanoparticles for immune modulation. Biomater. Sci. 2018, 7, 14–30.
  94. Dacoba, T.G.; Olivera, A.; Torres, D.; Crecente-Campo, J.; Alonso, M.J. Modulating the immune system through nanotechnology. Semin. Immunol. 2017, 34, 78–102.
  95. Gao, W.; Fang, R.H.; Thamphiwatana, S.; Luk, B.T.; Li, J.; Angsantikul, P.; Zhang, Q.; Hu, C.-M.J.; Zhang, L. Modulating Antibacterial Immunity via Bacterial Membrane-Coated Nanoparticles. Nano Lett. 2015, 15, 1403–1409.
  96. Gao, F.; Xu, L.; Yang, B.; Fan, F.; Yang, L. Kill the Real with the Fake: Eliminate Intracellular Staphylococcus aureus Using Nanoparticle Coated with Its Extracellular Vesicle Membrane as Active-Targeting Drug Carrier. ACS Infect. Dis. 2019, 5, 218–227.
  97. Geller, L.T.; Barzily-Rokni, M.; Danino, T.; Jonas, O.H.; Shental, N.; Nejman, D.; Gavert, N.; Zwang, Y.; Cooper, Z.A.; Shee, K.; et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 2017, 357, 1156–1160.
  98. Lehouritis, P.; Cummins, J.; Stanton, M.; Murphy, C.T.; McCarthy, F.O.; Reid, G.; Urbaniak, C.; Byrne, W.L.; Tangney, M. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci. Rep. 2015, 5, 14554.
  99. Kim, O.Y.; Choi, S.J.; Jang, S.C.; Park, K.S.; Kim, S.R.; Choi, J.P.; Lim, J.H.; Lee, S.W.; Park, J.; Di Vizio, D.; et al. Bacterial protoplast-derived nanovesicles as vaccine delivery system against bacterial infection. Nano Lett. 2015, 15, 266–274.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 384
Revisions: 2 times (View History)
Update Date: 24 Sep 2021
Video Production Service